Videos

Neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, improved overall survival in triple-negative breast cancer.

Response predictive subtype–guided treatment identified patient cohorts with breast cancer that were more likely to achieve pCR with Dato-DXd plus durvalumab.

As more therapies emerge for HER2-positive, -low, or -negative breast cancer, pathologists highlight the need for more precise methods of evaluating HER2 expression.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Updated data from a phase 1/2 study showed positive overall survival outcomes with Bria-IMT plus a checkpoint inhibitor in metastatic breast cancer.

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Experts on breast cancer discuss the potential adverse events related to trastuzumab deruxtecan (T-DXd).

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

RLY-2608 plus fulvestrant generated clinically meaningful PFS outcomes in PI3Kα-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Panelists discuss how to manage side effects of sacituzumab govitecan (SG), including counseling on alopecia, proactive management strategies, routine antiemetic premedications, and adjustments for chemotherapy-induced nausea and vomiting, as well as recommended breakthrough antinausea medications for home use.

Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.

Sara M. Tolaney, MD, MPH, discusses the utility of TROP2-directed antibody-drug conjugates in the treatment of patients with breast cancer.

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.

This discussion explores the occurrence and risk factors of neutropenia associated with SG treatment, comparing clinical practice experiences with trial data.

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Bruce G. Haffty, MD, MS, FACR, FASTRO, discusses the use of radiation in node-positive breast cancer patients who convert to node-negative status after neoadjuvant chemotherapy.

Jason A. Mouabbi, MD, discusses shifting standards for HER2 testing for T-DXd administration and areas of ongoing ADC development within breast cancer.

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

Bruce G. Haffty, MD, MS, discusses radiation therapy in node-positive breast cancer that becomes node negative after neoadjuvant chemotherapy.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Shipra Gandhi, MD, discusses factors influencing treatment decisions for patients with HR-positive breast cancer who have progressed on CDK4/6 inhibitors.

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.